AGLE - Aeglea BioTherapeutics, Inc.

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
5,805
2,329
18,739
0
0
Operating expenses
Research development
61,110
58,579
57,069
59,638
64,600
Selling general and administrative
30,756
28,531
27,319
21,843
15,734
Total operating expenses
91,866
87,110
84,388
81,481
80,334
Operating income or loss
-86,061
-84,781
-65,649
-81,481
-80,334
Total other income/expenses net
10
-7
-122
-5
-63
Income before tax
-85,590
-83,951
-65,660
-80,893
-78,254
Income tax expense
-151
-136
141
-
-
Income from continuing operations
-85,439
-83,815
-65,801
-80,893
-78,254
Net income
-85,439
-83,815
-65,801
-80,893
-78,254
Net income available to common shareholders
-85,439
-83,815
-65,801
-80,893
-78,254
Basic EPS
-
-0.99
-1.00
-1.52
-2.45
Diluted EPS
-
-0.99
-1.00
-1.52
-2.45
Basic average shares
-
84,281
65,745
53,372
31,950
Diluted average shares
-
84,281
65,745
53,372
31,950
EBITDA
-
-84,781
-65,649
-80,485
-80,334